Cytori Therapeutics Inc. said May 23 that it implemented a 1-for-10 reverse stock split.
The split reduced the San Diego cell therapy developer's outstanding stock to about 6.2 million shares from about 61.6 million shares. Fractional shares were rounded up to the nearest whole share.
Cytori Therapeutics expects the split to enable it to regain compliance with the Nasdaq Stock Market's bid price listing requirement.
